Literature DB >> 18618151

Protective effect of Epo on oxidative renal injury in rats with cyclosporine nephrotoxicity.

Belde Kasap1, Alper Soylu, Filiz Kuralay, Sülen Sarioglu, Müge Kiray, Kazim Tuğyan, Mehmet Türkmen, Salih Kavukcu.   

Abstract

The aim of our study was to determine the effect of recombinant human erythropoietin (rhEPO) on cyclosporine (CsA) nephrotoxicity. Twenty-six female Wistar rats were injected with 15 mg/kg subcutaneous CsA and intraperitoneal saline/rhEPO for 28 days. Four groups were formed: Group 1 (n = 5), a control group; Group 2 (n = 7), CsA + saline; Group 3 (n = 7), CsA + low dose (20 U/kg per day) rhEPO; Group 4 (n = 7), CsA + high dose (100 U/kg per day) rhEPO. Body weights, creatinine clearance, urinary protein/creatinine, hematocrit, serum creatinine levels, histopathological parameters, apoptosis and lipid peroxidation tests were compared between the three groups. Body weights and renal functions were similar in Groups 2, 3 and 4 rats but significantly lower than the values found for the control group at the end of the study. The hematocrit was significantly different between the four groups, showing a positive association with the strength of the injected rhEPO doses. Tubular and arteriolar damage was significantly lower in Groups 3 and 4 rats than in Group 2 rats, while chronic changes were similar between the three groups. TUNEL-positive cells and thiobabarbituric acid reacting substance (TBARS) levels were significantly higher in Group 2 rats, whereas superoxide dismutase levels were significantly lower in Group 2 rats than in those of the other three groups. Low or high dose rhEPO had no significant protective effects on body weight, renal functions, chronic fibrotic changes, but both doses reduced tubular and arteriolar changes, apoptotis and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618151     DOI: 10.1007/s00467-008-0903-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  32 in total

1.  Alpha-tocopherol and alpha-lipoic acid enhance the erythrocyte antioxidant defence in cyclosporine A-treated rats.

Authors:  Louise A Lexis; Robert G Fassett; Jeff S Coombes
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-01       Impact factor: 4.080

2.  A simple method for clinical assay of superoxide dismutase.

Authors:  Y Sun; L W Oberley; Y Li
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

3.  Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy.

Authors:  Seung Hun Lee; Can Li; Sun Woo Lim; Kyung Ohk Ahn; Bum Soon Choi; Yong Soo Kim; In Sung Moon; Jin Kim; Byung Kee Bang; Chul Woo Yang
Journal:  Am J Nephrol       Date:  2005-03-02       Impact factor: 3.754

4.  Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo.

Authors:  Nimesh S A Patel; Edward J Sharples; Salvatore Cuzzocrea; Prabal K Chatterjee; Domenico Britti; Muhammad M Yaqoob; Christoph Thiemermann
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

5.  Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake.

Authors:  L W Elzinga; S Rosen; W M Bennett
Journal:  J Am Soc Nephrol       Date:  1993-08       Impact factor: 10.121

6.  Erythropoietin protects against ischaemic acute renal injury.

Authors:  David A Vesey; Catherine Cheung; Betty Pat; Zoltan Endre; Glenda Gobé; David W Johnson
Journal:  Nephrol Dial Transplant       Date:  2004-02       Impact factor: 5.992

7.  Influence of cyclosporin A on the respiration of isolated rat kidney mitochondria.

Authors:  K Jung; M Pergande
Journal:  FEBS Lett       Date:  1985-04-08       Impact factor: 4.124

8.  Expression of apoptosis-related factors in chronic cyclosporine nephrotoxicity after cyclosporine withdrawal.

Authors:  Can Li; Sun-woo Lim; Bo-kyung Sun; Bum-soon Choi; Sylvia GLowacka; Akusib Cox; Darren Kelly; Yong-soo Kim; Jin Kim; Byung-kee Bang; Chul-woo Yang
Journal:  Acta Pharmacol Sin       Date:  2004-04       Impact factor: 6.150

Review 9.  Cyclosporine: 20 years of experience at the University of Munich.

Authors:  C Graeb; H Arbogast; M Guba; K-W Jauch; W Land
Journal:  Transplant Proc       Date:  2004-03       Impact factor: 1.066

10.  Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys.

Authors:  Naveen Tirkey; Gaganjit Kaur; Garima Vij; Kanwaljit Chopra
Journal:  BMC Pharmacol       Date:  2005-10-15
View more
  4 in total

1.  The epidemiological association of altitude with chronic kidney disease: Evidence of protective effect.

Authors:  Nasrollah Ghahramani; Faris Ahmed; Ammar Al-Laham; Eugene J Lengerich
Journal:  Nephrology (Carlton)       Date:  2011-02       Impact factor: 2.506

2.  Effects of long-acting erythropoietin analog darbepoetin-α on adriamycin-induced chronic nephropathy.

Authors:  Abdelaziz M Hussein; Mohamed Eldosoky; Ahmed Handhle; Hanaa Elserougy; Mohamed Sarhan; Mohamed A Sobh; Mahmoud El Hussiny; Eman M El Nashar
Journal:  Int Urol Nephrol       Date:  2015-12-10       Impact factor: 2.370

3.  Pharmacokinetic and nephroprotective benefits of using Schisandra chinensis extracts in a cyclosporine A-based immune-suppressive regime.

Authors:  Qiao Lai; Jiabao Wei; Mohammed Mahmoodurrahman; Chenxue Zhang; Shijian Quan; Tongming Li; Yang Yu
Journal:  Drug Des Devel Ther       Date:  2015-08-28       Impact factor: 4.162

4.  Expression of brain-derived neurotrophic factor in kidneys from normal and cyclosporine-treated rats.

Authors:  Yuan Sheng Tao; Shang Guo Piao; Ying Shun Jin; Ji Zhe Jin; Hai Lan Zheng; Hai Yan Zhao; Sun Woo Lim; Chul Woo Yang; Can Li
Journal:  BMC Nephrol       Date:  2018-03-14       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.